image
Healthcare - Biotechnology - NASDAQ - US
$ 29.14
-14.7 %
$ 3.76 B
Market Cap
-7.69
P/E
CASH FLOW STATEMENT
-453 M OPERATING CASH FLOW
-52.51%
-2.01 B INVESTING CASH FLOW
-159.36%
2.45 B FINANCING CASH FLOW
282.69%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Vaxcyte, Inc.
image
00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)(350m)(350m)(400m)(400m)(450m)(450m)(500m)(500m)2018201820192019202020202021202120222022202320232024202420252025
Net Income -464 M
Depreciation & Amortization 15.8 M
Capital Expenditures -22.4 M
Stock-Based Compensation 84.8 M
Change in Working Capital -54.9 M
Others -124 M
Free Cash Flow -475 M

Cash Flow

Millions
Dec-2024 Dec-2023 Dec-2022 Dec-2021 Dec-2020 Dec-2019 Dec-2018 Dec-2017
OPERATING CASH FLOW
Net Income (463.9) (402.3) (223.5) (100.1) (89.2) (50.3) (29.5) 17.2 K
Depreciation & Amortization 15.8 10.2 9.2 3.5 1.4 1.2 1.0 625
Deferred Income Tax 0 0 0 0 0.3 1 K 51 K 0
Stock Based Compensation 84.8 48.8 23.6 10.7 5.4 1.2 0.7 390
Other Operating Activities (34.5) (34.8) 7.3 1.5 0.2 (3.2) (4.7) 260
Change in Working Capital (54.9) 81.3 12.7 (37.0) 35.3 3.9 1.9 1 K
Cash From Operations (452.6) (296.8) (170.6) (121.4) (46.6) (47.1) (30.5) 15 K
INVESTING CASH FLOW
Capital Expenditures (22.4) (67.9) (5.8) (6.6) (1.2) (1.2) (1.8) 1.22 K
Other Items (1 983.2) (705.4) 80.4 (205.8) 50 K 0 1 K 106
Cash From Investing Activities (2 005.7) (773.3) 74.6 (212.3) (1.1) (1.2) (1.8) 1.12 K
FINANCING CASH FLOW
Common Stock Repurchased 0 0 0 0 0 0 0 0
Total Debt Repaid 0 0 0 0 61 K (0.3) (0.3) (0.2)
Dividends Paid 0 0 0 0 0 0 0 0
Other Financing Activities 12.9 3.8 5.1 3.9 110.9 41.8 62.5 0.2
Cash From Financing Activities 2 448.5 639.8 861.5 17.8 374.9 41.6 62.2 43.9 K
CHANGE IN CASH
Net Change In Cash (9.4) (437.0) 765.7 (316.3) 327.2 (7.1) 30.0 27.8 K
FREE CASH FLOW
Free Cash Flow (475.1) (364.7) (176.4) (127.9) (47.8) (48.3) (32.2) 16.2 K